Literature DB >> 5901568

Methyldopa in hypertension.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5901568      PMCID: PMC1843320     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  12 in total

1.  Merits of reducing high blood-pressure.

Authors:  A W LEISHMAN
Journal:  Lancet       Date:  1963-06-15       Impact factor: 79.321

2.  Treatment of severe hypertension with methyldopa.

Authors:  M HAMILTON; H KOPELMAN
Journal:  Br Med J       Date:  1963-01-19

3.  Methyldopa in the treatment of hypertension.

Authors:  R I BAYLISS; E A HARVEY-SMITH
Journal:  Lancet       Date:  1962-04-14       Impact factor: 79.321

4.  Methyldopa in hypertension. Clinical and pharmacological studies.

Authors:  C T DOLLERY; M HARINGTON
Journal:  Lancet       Date:  1962-04-14       Impact factor: 79.321

5.  Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

Authors:  L GILLESPIE; J A OATES; J R CROUT; A SJOERDSMA
Journal:  Circulation       Date:  1962-02       Impact factor: 29.690

6.  Effect of alpha-methyl DOPA in severe and malignant hypertension.

Authors:  P J CANNON; R T WHITLOCK; R C MORRIS; M ANGERS; J H LARAGH
Journal:  JAMA       Date:  1962-03-03       Impact factor: 56.272

7.  Hypertension: treated and untreated; a study of 400 cases.

Authors:  A W LEISHMAN
Journal:  Br Med J       Date:  1959-05-30

8.  The clinical course and pathology of hypertension with papilloedema (malignant hypertension).

Authors:  P KINCAID-SMITH; J McMICHAEL; E A MURPHY
Journal:  Q J Med       Date:  1958-01

9.  The natural history and course of hypertension with papilledema (malignant hypertension).

Authors:  M F SCHOTTSTAEDT; M SOKOLOW
Journal:  Am Heart J       Date:  1953-03       Impact factor: 4.749

10.  Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension.

Authors:  G ONESTI; A N BREST; P NOVACK; J H MOYER
Journal:  Am J Cardiol       Date:  1962-06       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.